文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.

作者信息

Zhao Claire Y, Greenstein Joseph L, Winslow Raimond L

机构信息

Department of Biomedical Engineering and the Institute for Computational Medicine, The Johns Hopkins University School of Medicine and Whiting School of Engineering, 3400 N Charles Street, Baltimore, MD 21218, USA.

出版信息

J Mol Cell Cardiol. 2016 Feb;91:215-27. doi: 10.1016/j.yjmcc.2016.01.004. Epub 2016 Jan 7.


DOI:10.1016/j.yjmcc.2016.01.004
PMID:26773602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4764497/
Abstract

The balanced signaling between the two cyclic nucleotides (cNs) cAMP and cGMP plays a critical role in regulating cardiac contractility. Their degradation is controlled by distinctly regulated phosphodiesterase isoenzymes (PDEs), which in turn are also regulated by these cNs. As a result, PDEs facilitate communication between the β-adrenergic and Nitric Oxide (NO)/cGMP/Protein Kinase G (PKG) signaling pathways, which regulate the synthesis of cAMP and cGMP respectively. The phenomena in which the cAMP and cGMP pathways influence the dynamics of each other are collectively referred to as cN cross-talk. However, the cross-talk response and the individual roles of each PDE isoenzyme in shaping this response remain to be fully characterized. We have developed a computational model of the cN cross-talk network that mechanistically integrates the β-adrenergic and NO/cGMP/PKG pathways via regulation of PDEs by both cNs. The individual model components and the integrated network model replicate experimentally observed activation-response relationships and temporal dynamics. The model predicts that, due to compensatory interactions between PDEs, NO stimulation in the presence of sub-maximal β-adrenergic stimulation results in an increase in cytosolic cAMP accumulation and corresponding increases in PKA-I and PKA-II activation; however, the potentiation is small in magnitude compared to that of NO activation of the NO/cGMP/PKG pathway. In a reciprocal manner, β-adrenergic stimulation in the presence of sub-maximal NO stimulation results in modest cGMP elevation and corresponding increase in PKG activation. In addition, we demonstrate that PDE2 hydrolyzes increasing amounts of cAMP with increasing levels of β-adrenergic stimulation, and hydrolyzes increasing amounts of cGMP with decreasing levels of NO stimulation. Finally, we show that PDE2 compensates for inhibition of PDE5 both in terms of cGMP and cAMP dynamics, leading to cGMP elevation and increased PKG activation, while maintaining whole-cell β-adrenergic responses similar to that prior to PDE5 inhibition. By defining and quantifying reactions comprising cN cross-talk, the model characterizes the cross-talk response and reveals the underlying mechanisms of PDEs in this non-linear, tightly-coupled reaction system.

摘要

相似文献

[1]
Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.

J Mol Cell Cardiol. 2016-2

[2]
Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

J Mol Cell Cardiol. 2015-11

[3]
Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation.

J Mol Cell Cardiol. 2017-5

[4]
Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.

Cardiovasc Res. 2015-4-7

[5]
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway.

Circ Res. 2006-2-3

[6]
PDE2 at the crossway between cAMP and cGMP signalling in the heart.

Cell Signal. 2017-6-28

[7]
Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.

J Neurosci. 2003-7-23

[8]
Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.

Biochem J. 2001-11-15

[9]
cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology.

Circ Res. 2007-6-8

[10]
Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts.

Int J Mol Sci. 2022-2-15

引用本文的文献

[1]
Exploring the mechanisms underlying effects of bisphenol a on cardiovascular disease by network toxicology and molecular docking.

Heliyon. 2024-5-17

[2]
Simulated Microgravity and Hypergravity Affect the Expression Level of Soluble Guanylate Cyclase, Adenylate Cyclase, and Phosphodiesterase Genesin Rat Ventricular Cardiomyocytes.

Bull Exp Biol Med. 2024-1

[3]
Regulation of the renin-angiotensin-aldosterone system by cyclic nucleotides and phosphodiesterases.

Front Endocrinol (Lausanne). 2023

[4]
Effects of cGMP/Akt/GSK-3β signaling pathway on atrial natriuretic peptide secretion in rabbits with rapid atrial pacing.

Front Physiol. 2022-8-19

[5]
Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors.

Pharmaceuticals (Basel). 2022-8-19

[6]
Cyclic GMP and PKG Signaling in Heart Failure.

Front Pharmacol. 2022-4-11

[7]
Proteomic Analysis of the Role of the Adenylyl Cyclase-cAMP Pathway in Red Blood Cell Mechanical Responses.

Cells. 2022-4-6

[8]
Identification of major depressive disorder disease-related genes and functional pathways based on system dynamic changes of network connectivity.

BMC Med Genomics. 2021-2-23

[9]
Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases.

Int J Mol Sci. 2020-10-10

[10]
Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.

Cardiovasc Drugs Ther. 2020-6

本文引用的文献

[1]
Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

J Mol Cell Cardiol. 2015-11

[2]
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.

Nature. 2015-3-26

[3]
Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy.

Circ Res. 2015-2-16

[4]
Advances in targeting cyclic nucleotide phosphodiesterases.

Nat Rev Drug Discov. 2014-4

[5]
Nitric oxide synthase regulation of cardiac excitation-contraction coupling in health and disease.

J Mol Cell Cardiol. 2014-8

[6]
Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes.

Circ Res. 2014-3-5

[7]
Mechanisms of cyclic AMP compartmentation revealed by computational models.

J Gen Physiol. 2014-1

[8]
Cyclic AMP compartments and signaling specificity: role of cyclic nucleotide phosphodiesterases.

J Gen Physiol. 2014-1

[9]
Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes.

J Am Coll Cardiol. 2013-6-26

[10]
The role of phosphodiesterases in bladder pathophysiology.

Nat Rev Urol. 2013-5-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索